Posted Date: January 11, 2011
Quality of life measures tend to be most useful for clinical decision-making in trials in which quality of life is the primary outcome, according to a recent study published online January 7 in The Journal of the National Cancer Institute.
Quality of life measures tend to be most useful for clinical decision-making in trials in which quality of life is the primary outcome, according to a recent study published online January 7 in The Journal of the National Cancer Institute.
There has been increasing interest, by a number of groups including the FDA and the World Health Organization, in the value of patient-reported symptom assessment in trials and their potential usage as primary or secondary endpoints in new trials.